Join BIOCYTOGEN at 2nd Cell Therapy For Autoimmune Disease Summit

We’re thrilled to announce our participation as an exhibitor at the 2nd Cell Therapy For Autoimmune Disease Summit! From December 2nd to 3rd in Philadelphia, this esteemed conference will bring together leading experts and innovators to exchange insights, explore groundbreaking ideas, and propel advancements in cell therapy for autoimmune diseases.

What is the 2nd Cell Therapy For Autoimmune Disease Summit?

The 2nd Cell Therapy for Autoimmune Disease Summit is the premier event dedicated to advancing cell therapies within the autoimmune space. This year’s conference will gather over 30 trailblazers, including leaders from Cartesian Therapeutics, Bristol Myers Squibb, the University of Pennsylvania, and ImmPACT Bio, who will present clinical updates, next-gen candidates, novel antigen targets, and innovative biomarkers—each critical for accelerating cell therapy development in autoimmune disease.

With a brand-new, two-track agenda, attendees can dive deep into both preclinical development and clinical strategy, gaining insights to elevate their therapeutic candidates alongside industry pioneers. As the largest edition yet, this event promises an expanded community and fresh opportunities for breakthrough ideas. Designed to inspire innovation, this summit facilitates the exchange of best-in-class approaches for developing transformative cell-based therapies for autoimmune patients.

Event Overview  

Date: December 2nd 08:30 am – 3rd 05:00 pm 

Venue: Sheraton Philadelphia Downtown, 201 N 17th Street, Philadelphia, PA 19103, United States

Event Schedule

The 2nd Cell Therapy For Autoimmune Disease Summit in Philadelphia will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the 2nd Cell Therapy For Autoimmune Disease Summit agenda.

About BIOCYTOGEN

Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).

We look forward to seeing you at the 2nd Cell Therapy For Autoimmune Disease Summit in Philadelphia!